Mesoblast Limited (NASDAQ: MESO) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.72 | Insider Own | 10.98% | Shs Outstand | 129.70M | Perf Week | 2.42% |
| Market Cap | 1.92B | Forward P/E | 19.45 | EPS next Y | 0.76 | Insider Trans | 59.75% | Shs Float | 82.47M | Perf Month | 3.28% |
| Enterprise Value | 1.92B | PEG | - | EPS next Q | -0.07 | Inst Own | - | Short Float | 3.80% | Perf Quarter | -7.50% |
| Income | -94.00M | P/S | 29.08 | EPS this Y | 100.65% | Inst Trans | - | Short Ratio | 16.07 | Perf Half Y | -13.90% |
| Sales | 66.00M | P/B | 3.34 | EPS next Y | 16136.02% | ROA | -12.06% | Short Interest | 3.13M | Perf YTD | -17.96% |
| Book/sh | 4.43 | P/C | 14.77 | EPS next 5Y | 630.94% | ROE | -16.10% | 52W High | 21.50 -31.16% | Perf Year | -2.44% |
| Cash/sh | 1.00 | P/FCF | - | EPS past 3/5Y | - | ROIC | -20.16% | 52W Low | 12.66 16.90% | Perf 3Y | 85.00% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 19.35% -11.88% | Gross Margin | -53.34% | Volatility | 2.61% 3.72% | Perf 5Y | 5.11% |
| Dividend TTM | - | EV/Sales | 29.13 | EPS Y/Y TTM | 19.10% | Oper. Margin | -223.08% | ATR (14) | 0.66 | Perf 10Y | 72.09% |
| Dividend Ex-Date | - | Quick Ratio | 1.41 | Sales Y/Y TTM | 1000.00% | Profit Margin | -144.33% | RSI (14) | 46.91 | Recom | 2.73 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.58 | EPS Q/Q | -11.07% | SMA20 | -5.53% | Beta | 2.07 | Target Price | 11.50 |
| Payout | 0.00% | Debt/Eq | 0.21 | Sales Q/Q | 1200.00% | SMA50 | -0.69% | Rel Volume | 0.55 | Prev Close | 14.47 |
| Employees | 81 | LT Debt/Eq | 0.12 | Earnings | Sep 04 | SMA200 | -7.80% | Avg Volume | 216.21K | Price | 14.80 |
| IPO Date | Jan 20, 2010 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -310.01% 75.83% | Net Debt/EBITDA | -0.09 | Volume | 118,306 | Change | 2.28% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Nov-25-25 | Upgrade | Jefferies | Hold → Buy | |
| Jul-18-25 | Downgrade | Jefferies | Buy → Hold | |
| Dec-23-24 | Downgrade | Jefferies | Buy → Hold | |
| Sep-24-24 | Reiterated | Maxim Group | Hold | $12 |
| Jul-23-24 | Upgrade | Piper Sandler | Neutral → Overweight | $11 |
| Aug-30-23 | Upgrade | Jefferies | Hold → Buy | |
| Aug-06-23 | Downgrade | Maxim Group | Buy → Hold | |
| Aug-03-23 | Downgrade | Piper Sandler | Overweight → Neutral | |
| Aug-03-23 | Downgrade | William Blair | Outperform → Market Perform | |
| Dec-05-22 | Downgrade | Jefferies | Buy → Hold |
Mesoblast Limited is a biopharmaceutical firm dedicated to the development and commercialization of allogeneic cell-based therapies. Its global presence extends across the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company addresses a broad spectrum of medical conditions, including cardiovascular, spinal orthopedic disorders, oncology, hematology, and immune-mediated and inflammatory diseases. At the core of its innovation is a proprietary regenerative medicine platform utilizing specialized mesenchymal lineage cells. Currently, several of Mesoblast's leading product candidates are undergoing Phase III clinical trials: remestemcel-L, designed for severe, steroid-refractory acute graft versus host disease and acute respiratory distress syndrome associated with COVID-19; Rexlemestrocel-L, aimed at advanced chronic heart failure; and MPC-06-ID, intended for chronic low back pain stemming from degenerative disc disease. Additionally, MPC-300-IV is being developed for biologic-refractory rheumatoid arthritis and diabetic nephropathy. The company has cultivated strategic partnerships to advance its pipeline and market reach. These collaborations include Tasly Pharmaceutical Group for the distribution of MPC-150-IM (heart failure) and MPC-25-IC (heart attacks) in China; JCR Pharmaceuticals Co. Ltd. for therapies addressing wound healing in patients with epidermolysis bullosa; and Grünenthal for the development and commercialization of cell therapy solutions for chronic low back pain. Mesoblast Limited was established in 2004 and maintains its headquarters in Melbourne, Australia.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 6/30/2025 | FY 2024 6/30/2024 | FY 2023 6/30/2023 | FY 2022 6/30/2022 | FY 2021 6/30/2021 | FY 2020 6/30/2020 | FY 2019 6/30/2019 | FY 2018 6/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 66 | 17 | 6 | 8 | 10 | 7 | 32 | 17 | 17 | |
| Cost of Goods Sold Incl. D&A | 100 | 5 | 41 | 55 | 64 | 86 | 81 | 75 | 6 | |
| Gross Profit | -34 | 12 | -35 | -47 | -53 | -78 | -49 | -58 | 12 | |
| Selling, General and Administrative Excl. Other | 50 | 39 | 24 | 53 | 58 | 64 | 51 | 37 | 27 | |
| Research and Development | 60 | 35 | 25 | 27 | 33 | 53 | 56 | 60 | 66 | |
| Other Operating Expense | 0 | 1 | 0 | -3 | 0 | -2 | 1 | 1 | -1 | |
| Operating Income | -146 | -62 | -84 | -69 | -81 | -109 | -75 | -80 | -77 | |
| Interest Expense | 0 | 23 | 21 | 19 | 17 | 11 | 15 | 12 | 2 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 52 | -16 | 17 | 7 | 6 | 20 | 2 | -7 | 13 | |
| Net Income Before Taxes | -94 | -102 | -88 | -82 | -92 | -100 | -87 | -99 | -66 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | -1 | -9 | -9 | -31 | |
| Consolidated Net Income | -94 | -102 | -88 | -82 | -91 | -99 | -78 | -90 | -35 | |
| Net Income From Continuing Operations | -94 | -102 | -88 | -82 | -91 | -99 | -78 | -90 | -35 | |
| Net Income | -94 | -102 | -88 | -82 | -91 | -99 | -78 | -90 | -35 | |
| EPS (Recurring) | -0.72 | -0.84 | -0.89 | -0.98 | -1.30 | -1.60 | -1.50 | -1.80 | -0.76 | |
| EPS (Basic, Before Extraordinaries) | -0.72 | -0.84 | -0.89 | -0.98 | -1.30 | -1.60 | -1.50 | -1.80 | -0.76 | |
| EPS (Diluted) | -0.72 | -0.84 | -0.89 | -0.98 | -1.30 | -1.60 | -1.50 | -1.80 | -0.76 | |
| EBITDA | -66 | -74 | -56 | -59 | -77 | -85 | -69 | -85 | -75 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 28.93 | 77.51 | 112.37 | 82.11 | 30.19 | 130.37 | 37.73 | 30.61 | 30.41 | |
| Gross Margin | -51.52 | 70.59 | -583.33 | -587.50 | -530.00 | -1,114.29 | -153.13 | -341.18 | 70.59 | |
| Operating Margin | -221.21 | -364.71 | -1,400.00 | -862.50 | -810.00 | -1,557.14 | -234.38 | -470.59 | -452.94 | |
| Net Margin | -142.42 | -600.00 | -1,466.67 | -1,025.00 | -910.00 | -1,414.29 | -243.75 | -529.41 | -205.88 | |
| Shares Outstanding | 129 | 121 | 99 | 84 | 68 | 61 | 53 | 49 | 47 | |
| Market Capitalization | 1,909 | 1,318 | 674 | 657 | 302 | 913 | 1,207 | 520 | 517 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| George Gregory | director, 10 percent owner: | Apr 09 '26 | Buy | 4.96 | 2,181,890 | 10,829,564 | 13,586,890 | Apr 13 |
| George Gregory | director, 10 percent owner: | Apr 10 '26 | Buy | 1.48 | 2,324,072 | 3,439,627 | 8,324,072 | Apr 10 |
| George Gregory | director, 10 percent owner: | Apr 04 '26 | Buy | 1.42 | 4,000,000 | 5,680,000 | 12,000,000 | Apr 10 |